CAMBRIDGE, Mass., May 14, 2007 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced today Richard P. Shea, Vice President and Chief Financial Officer, will present at the Acumen BioFion Rodman & Renshaw 4th Annual Global Healthcare Conference on Tuesday, May 15, 2007 at 12:35 PM CEST (6:35 AM EDT) at the Le Meridien Beach Plaza Hotel, in Monte Carlo, Monaco. A live audio webcast of the presentation will be available on the "Investors" section of the Company's website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately thirty minutes after the event and will be available through June 14, 2007.
About Momenta
Momenta is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. The Company's most advanced product candidate, M-Enoxaparin is designed to be a technology-enabled generic version of Lovenox(r). Momenta's first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. Within the Company's discovery program, it is seeking to discover and develop novel therapeutics by applying its technology to better understand sugars' functions in biological processes, with an initial focus in oncology. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.